This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
Full Title of Study: “A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s Disease”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: January 2011
A randomized, double-blind, active-control, parallel-group 13-week comparison of IPX066 versus regular carbidopa-levodopa (CD-LD). Prior to randomization, subjects on a stable regular LD regimen will enter a 3-week dose-adjustment period for IR CD-LD, followed by a 6-week dose-conversion period to IPX066.
- Drug: IPX066
- extended-release carbidopa-levodopa capsules
- Drug: IR CD-LD
- immediate-release carbidopa-levodopa tablets
Arms, Groups and Cohorts
- Experimental: IPX066
- Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.
- Active Comparator: IR CD-LD
- Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).
Clinical Trial Outcome Measures
- Percentage of “Off” Time During Waking Hours at End of Study
- Time Frame: 22 weeks
- Percentage of “off” time during waking hours at end of study is measured by using the Parkinson’s disease diary. “Off” time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease).”
- “Off” Time
- Time Frame: 22 weeks
- “Off” time hours is measured by using the Parkinson’s disease diary. “Off” time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease).”
- “On” Time Without Troublesome Dyskinesia
- Time Frame: 22 weeks
- “On” time without troublesome dyskinesiais measured by using the Parkinson’s disease diary. “On” time without troublesome dyskinesia describes a period when the participant experiences decreased Parkinsonian symptoms (e.g. immobility or inability to move with ease) without dyskinesia (i.e. difficulty in performing voluntary movements) that affect daily living.”
Participating in This Clinical Trial
1. Diagnosed with idiopathic PD.
2. At least 30 years old at the time of PD diagnosis.
3. Currently being treated with IR LD (CD-LD or benserazide-LD) and on a stable regimen of IR LD for at least 4 weeks and:
- Requiring a total daily IR LD dose of at least 400 mg
- Having a minimum dosing frequency of four times per day.
4. Able to differentiate "on" state from "off" state.
5. Have predictable "off" periods.
6. Amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors (e.g., selegiline, rasagiline) or dopamine agonists are allowed as long as the doses and regimens have been stable for at least 4 weeks prior to Screening and the therapy is intended to be constant throughout the course of the study.
7. Agrees to use a medically acceptable method of contraception throughout the study and for 1 month afterward.
1. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.
2. Nonresponsive to LD therapy.
3. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) or if such procedures are anticipated during study participation.
4. Received within 4 weeks or planning to take during participation in the clinical study: any controlled-release LD product, additional CD (e.g., Lodosyn®) or benserazide (e.g. Serazide®), catechol-O-methyl transferase inhibitors (e.g., entacapone and tolcapone), nonselective MAO inhibitors, apomorphine, and antipsychotics including neuroleptic agents for the purpose of treating psychosis or bipolar disorder.
5. Allergic to Yellow Dye #5 (tartrazine).
6. History of or currently active psychosis.
7. Active or prior medical conditions such as peptic ulcers or prior surgical (e.g., bowel) procedures that would interfere with LD absorption.
8. Active or history of narrow-angle glaucoma.
9. A history of malignant melanoma or a suspicious undiagnosed skin lesion.
10. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis.
11. Received any investigational medications during the 4 weeks prior to Screening.
12. Unable to swallow large pills (e.g., large vitamin pills).
13. Pregnant or breastfeeding.
14. Subjects who are unable to complete a symptom diary.
Gender Eligibility: All
Minimum Age: 30 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Impax Laboratories, LLC
- Provider of Information About this Clinical Study
- Overall Official(s)
- Impax Study Director, Study Director, Impax Laboratories, LLC
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.